JPS59122425A - 持続性製剤およびその製造法 - Google Patents

持続性製剤およびその製造法

Info

Publication number
JPS59122425A
JPS59122425A JP23452182A JP23452182A JPS59122425A JP S59122425 A JPS59122425 A JP S59122425A JP 23452182 A JP23452182 A JP 23452182A JP 23452182 A JP23452182 A JP 23452182A JP S59122425 A JPS59122425 A JP S59122425A
Authority
JP
Japan
Prior art keywords
long
tablet
drug
lipid
surfactant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP23452182A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0460090B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html
Inventor
Kiyoji Koyari
小鑓　喜代治
Suehiro Matsuda
松田　末広
Akira Ito
亮 伊藤
Masayuki Hasegawa
正行 長谷川
Shinichi Kimura
新一 木村
Takao Goto
孝夫 後藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaken Pharmaceutical Co Ltd
Original Assignee
Kaken Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharmaceutical Co Ltd filed Critical Kaken Pharmaceutical Co Ltd
Priority to JP23452182A priority Critical patent/JPS59122425A/ja
Publication of JPS59122425A publication Critical patent/JPS59122425A/ja
Publication of JPH0460090B2 publication Critical patent/JPH0460090B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
JP23452182A 1982-12-27 1982-12-27 持続性製剤およびその製造法 Granted JPS59122425A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP23452182A JPS59122425A (ja) 1982-12-27 1982-12-27 持続性製剤およびその製造法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP23452182A JPS59122425A (ja) 1982-12-27 1982-12-27 持続性製剤およびその製造法

Publications (2)

Publication Number Publication Date
JPS59122425A true JPS59122425A (ja) 1984-07-14
JPH0460090B2 JPH0460090B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-09-25

Family

ID=16972323

Family Applications (1)

Application Number Title Priority Date Filing Date
JP23452182A Granted JPS59122425A (ja) 1982-12-27 1982-12-27 持続性製剤およびその製造法

Country Status (1)

Country Link
JP (1) JPS59122425A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61158921A (ja) * 1984-10-13 1986-07-18 ドロルギ−ト・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング・ウント・コンパニ−・コマンデツト・ゲゼルシヤフト イブプロフエン含有ゼラチン軟カプセルおよびその製造方法
JPS62111922A (ja) * 1985-10-03 1987-05-22 ザ　ブ−ツ　カンパニ−　ピ−エルシ− 薬用組成物
US4867987A (en) * 1986-06-25 1989-09-19 Mepha Ag Pharmaceutical product for the sustained release of ibuprofen
JPH11322621A (ja) * 1998-04-30 1999-11-24 Ved Vesely Renata Maria Anna Cavaliere 乳酸杆菌属の菌類を含有する膣感染症を治療するための薬学的組成物
WO2004058137A3 (fr) * 2002-12-23 2005-04-14 Aventis Pharma Sa Compositions pour administration orale de principes actifs necessitant un masquage du gout
US7815934B2 (en) 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF PHARMACEUTICAL SCIENCES=1966 *
JOURNAL OF PHARMACEUTICAL SCIENCES=1968 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61158921A (ja) * 1984-10-13 1986-07-18 ドロルギ−ト・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング・ウント・コンパニ−・コマンデツト・ゲゼルシヤフト イブプロフエン含有ゼラチン軟カプセルおよびその製造方法
JPS62111922A (ja) * 1985-10-03 1987-05-22 ザ　ブ−ツ　カンパニ−　ピ−エルシ− 薬用組成物
US4867987A (en) * 1986-06-25 1989-09-19 Mepha Ag Pharmaceutical product for the sustained release of ibuprofen
JPH11322621A (ja) * 1998-04-30 1999-11-24 Ved Vesely Renata Maria Anna Cavaliere 乳酸杆菌属の菌類を含有する膣感染症を治療するための薬学的組成物
US7815934B2 (en) 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
WO2004058137A3 (fr) * 2002-12-23 2005-04-14 Aventis Pharma Sa Compositions pour administration orale de principes actifs necessitant un masquage du gout
AU2003299360B2 (en) * 2002-12-23 2009-10-29 Aventis Pharma S.A. Compounds for oral dosage of active substances requiring a taste masking

Also Published As

Publication number Publication date
JPH0460090B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-09-25

Similar Documents

Publication Publication Date Title
US3773920A (en) Sustained release medicinal composition
US5104648A (en) High ibuprofen content granulations
EP1810676B1 (en) Levetiracetam formulations and methods for their manufacture
NO313124B1 (no) Anvendelse av tramadol i fremstillingen av et medikament for behandling av smerte
US4911921A (en) High ibuprofen content granulations
JP2011225592A (ja) 放出制御トラマドールの漸増投薬処方
CN107737112B (zh) 一种来曲唑片及其制备方法
JP3836507B2 (ja) （ｓ）−２−（４−イソブチルフェニル）プロピオン酸を活性成分とし、微結晶セルロースおよびコロイダルシリカを賦形剤とする固形医薬組成物
JP5881700B2 (ja) ブロナンセリン経口放出制御型医薬組成物
JPS59122425A (ja) 持続性製剤およびその製造法
DE60027601T2 (de) Arzneizubereitung mit kontrollierter freisetzung enthaltend tramadol hydrochlorid
US20240415777A1 (en) Instant release pharmaceutical preparation of anticoagulant and preparation method therefor
CN108420798A (zh) 一种抗凝剂的速释药物制剂及其制备方法
JP2020180101A (ja) レベチラセタム含有医薬組成物の製造方法
EP2946771B1 (en) Water-dispersible tablet formulation comprising deferasirox
EP1128820B1 (en) Pharmaceutical mixture comprising a combination of a profen and other active compounds
EP3511001B1 (en) Pirfenidone-containing tablet and capsule formulation
KR102373089B1 (ko) 이부프로펜 및 아세트아미노펜을 포함하는 약제학적 조성물 및 이의 제조방법
JP2638604B2 (ja) 徐放性製剤
MXPA01005918A (es) Mezcla faramaceutica que comprende un profeno.
JPH0474137A (ja) 徐放性製剤用基剤粉末
JP6920564B1 (ja) 固形製剤
JP4367722B2 (ja) マルチプルユニットタイプ徐放性錠剤
KR20080020165A (ko) 국소적으로 가용화 된 난용성 약물의 제어 방출형 제제조성물 및 그의 제조 방법
Nyavanandi Novel Applications of Hot Melt Extrusion for Developing Oral Solid Dosage Forms with Improved Solubility, Permeability, and Stability